Severe Combined Immunodeficiency (SCID)
Primary Humoral & Cellular Immunodeficiency Syndrome
Primary risk age: Infants (Presents in the first few months of life with severe infections)
- Urgency
- Severe
- Typical age
- Infants (Presents in the first few months of life with severe infections)
- Body system
- Immunological & Allergic
Typical course: This is a life-threatening genetic immunodeficiency; bone marrow transplant recovery and immune reconstitution take 6 to 12 months.
Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13
1. Summary & Pathophysiology
Primary Humoral & Cellular Immunodeficiency Syndrome
Pathophysiology (Development Path)
The genetic defect disrupts essential cytokine signaling or enzyme pathways required for lymphocyte maturation. The complete absence of functional T-cells and secondary failure of antibody production leaves the infant defenseless against viral, bacterial, and fungal pathogens.
Primary Causes & Etiology
Genetic mutations (most commonly X-linked, caused by a mutation in the IL2RG gene; or autosomal recessive, due to ADA deficiency), causing a failure of T-cell, B-cell, and NK-cell development.
2. Symptom Continuum
- Early Onset Signs
Recurrent, severe bacterial infections, persistent oral thrush (candidiasis), and diaper rashes that do not respond to standard treatments.
- Progressive Phase
Failure to thrive, chronic intractable diarrhea, and recurrent opportunistic infections (such as Pneumocystis jirovecii pneumonia).
- Severe Indicators
Generalized erythroderma (GVHD from maternal T-cells crossing the placenta), severe interstitial pneumonia, disseminated viral infections, and death before age 1 if untreated.
3. Clinical Verification
Newborn screening measuring T-cell Receptor Excision Circles (TRECs) from a heel stick. Confirmed by flow cytometry showing absent or extremely low T-cell counts, and genetic testing.
4. Care & Elements Plan
Primary Care Treatment Plan
Place the infant in strict protective isolation (reverse isolation). Initiate prophylactic antibiotics and antifungals. Administer intravenous immunoglobulin (IVIG) replacement. The curative treatment is a hematopoietic stem cell transplant (bone marrow transplant) or gene therapy.
Home Support Elements
Avoid all public spaces, sick contacts, and unboiled water. Administer prophylactic medications consistently. Maintain a sterile environment.
Generic Active Ingredients (No Brands)
- Intravenous Immunoglobulin (IVIG - active antibodies to provide passive immunity)
- Trimethoprim-Sulfamethoxazole (prophylactic antibiotic for Pneumocystis)
- Fluconazole (active antifungal to prevent systemic candidiasis).
Lists active elements only. Never administer self-designed therapies.
5. Doctor Critical Lines
Critical Thresholds: When to See a Doctor
Any positive newborn screening for TREC, or an infant with recurrent severe infections, thrush, and failure to thrive requires immediate immunological evaluation.
6. Vaccine & Prevention
Routine Prophylaxis (Prevention)
Avoid all exposure to potential pathogens. Genetic counseling for carrier parents.
Immunization Context
Live viral or bacterial vaccines (such as Rotavirus, MMR, Varicella, and BCG) are strictly contraindicated and can be fatal.
7. Timelines & Outlook
Active Timeline
This is a life-threatening genetic immunodeficiency; bone marrow transplant recovery and immune reconstitution take 6 to 12 months.
Expected Prognosis
Excellent if a bone marrow transplant is performed in the first 3 months of life (survival >90%). It is universally fatal by age 1 to 2 if untreated.
Potential Untreated Complications
Opportunistic infections, GVHD, nutritional failure, organ damage, and death.
